<DOC>
	<DOCNO>NCT01206036</DOCNO>
	<brief_summary>In Phase I study safety combination Docetaxel Temsirolimus need show study expand Phase II study examine activity safe combination Temsirolimus Docetaxel comparison Docetaxel alone .</brief_summary>
	<brief_title>CESAR Study Prostate Cancer With Temsirolimus Added Standard Docetaxel Therapy ( CEPTAS )</brief_title>
	<detailed_description>The purpose Phase I study evaluate feasibility dose level DL1 , DL2 DL3 ( combination Temsirolimus Docetaxel ) define recommend dose ( RD ) Phase II part use dose level dose escalate scheme . Secondary objective collection safety data dose level use part .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria Phase I Part : Adult male ≥18 year age . Patients CRPC define confirm rise PSA level orchiectomy LHRH agonist base therapy . Progressive disease , define PSA progression confirm rise PSA level . PSA time study entry ≥2ng/ml within 1 week prior treatment ( accord Scher 2008 ) . Bone metastasis and/or lymph node and/or visceral organ metastasis allow . Measurable non measurable disease allow . Performance status ( PS ) 01 ECOG . Signed write informed consent . White blood cell count ( WBC ) ≥4x10^9/L neutrophils ≥1.5x10^9/L , platelet count ≥100x10^9/L , hemoglobin ≥9g/dL . Total bilirubin &lt; =2 x upper limit normal . AST ALT &lt; =2.5 x upper limit normal , &lt; =5 x upper limit normal case liver metastasis . Serum creatinine &lt; =1.5 x upper limit normal creatinine clearance &gt; 60 ml/min . Androgen ablation continue . Antiandrogens bicalutamide discontinue least 4 week prior start study treatment . Exclusion Criteria Phase I Part : Clinically symptomatic brain meningeal metastasis . Receiving know strong CYP3A4 isoenzyme inhibitor and/or inducer . Any investigational drug within 30 day inclusion . Not recovered prior biopsy , surgery , traumatic injury , and/or radiation therapy , judge investigator . Nonhealing wound ulcer . Grade ≥ 3 hemorrhage within past month . Any condition / concomitant disease allow chemotherapy docetaxel , prednisone temsirolimus discretion treat physician , like : Renal insufficiency require dialysis ; congestive heart failure uncontrolled angina pectoris ; prior myocardial infarction within 6 month start chemotherapy ; uncontrolled severe hypertension ( failure diastolic blood pressure fall 90 mm Hg despite use ≥ 3 antihypertensive drug ) arrhythmias ; instable diabetes mellitus , ulceration diabetes mellitus condition allow high dose corticosteroid ; effusion pericardium , pleura abdomen symptomatic need puncture . Known hypersensitivity component temsirolimus infusion medical reason able receive adequate premedication ( antihistamine agent ) . Legal incapacity limit legal capacity Medical psychological condition would permit patient complete study sign inform consent . Inclusion Criteria Phase II Part , Chemotherapy Period : Adult male ≥ 18 year age . Patients CRPC define confirm rise PSA level orchiectomy LHRH agonist base therapy Progressive disease , define PSA progression confirm rise PSA level PSA time study entry ≥ 2ng/ml within 1 week prior treatment ( accord Scher 2008 ) . Bone metastasis and/or lymph node and/or visceral organ metastasis allow . Measurable non measurable disease allow . Performance status ( PS ) 01 ECOG . Signed write informed consent . White blood cell count ( WBC ) ≥4x10^9/L neutrophils ≥1.5x10^9/L , platelet count ≥100x10^9/L , hemoglobin ≥9g/dL . Total bilirubin &lt; = 2 x upper limit normal . AST ALT &lt; =2.5 x upper limit normal , &lt; =5 x upper limit normal case liver metastasis . Serum creatinine &lt; =1.5 x upper limit normal creatinine clearance &gt; 60 ml/min . Androgen ablation continue . Antiandrogens bicalutamide discontinue least 4 week prior start study treatment . Exclusion Criteria Phase II Part , Chemotherapy Period : Prior Chemotherapy . Clinically symptomatic brain meningeal metastasis . Receiving know strong CYP3A4 isoenzyme inhibitor and/or inducer . Any investigational drug within 30 day inclusion . Not recovered prior biopsy , surgery , traumatic injury , and/or radiation therapy , judge investigator . Nonhealing wound ulcer . Grade ≥ 3 hemorrhage within past month . Any condition / concomitant disease allow chemotherapy docetaxel , prednisone temsirolimus discretion treat physician , like : Renal insufficiency require dialysis ; congestive heart failure uncontrolled angina pectoris ; prior myocardial infarction within 6 month start chemotherapy ; uncontrolled severe hypertension ( failure diastolic blood pressure fall 90 mm Hg despite use ≥ 3 antihypertensive drug ) arrhythmias ; instable diabetes mellitus , ulceration diabetes mellitus condition allow high dose corticosteroid ; effusion pericardium , pleura abdomen symptomatic need puncture . Known hypersensitivity component temsirolimus infusion medical reason able receive adequate premedication ( antihistamine agent ) . Legal incapacity limit legal capacity . Medical psychological condition would permit patient complete study sign inform consent . Inclusion Criteria Phase II Part , Maintenance Period : Completed 8 cycle ( 26 week ) treatment Arm A White blood cell count ( WBC ) ≥4x10^9/L neutrophils ≥1.5x10^9/L , platelet count ≥100x10^9/L , hemoglobin ≥9g/dL . Total bilirubin &lt; =2 x upper limit normal . AST ALT &lt; =2.5 x upper limit normal , &lt; =5 x upper limit normal case liver metastasis . Serum creatinine &lt; =1.5 x upper limit normal creatinine clearance &gt; 60 ml/min . General condition sufficient allow therapy temsirolimus . Signed Informed Consent . Exclusion Criteria Phase II Part , Maintenance Period : Disease Progression first 8 cycle ( 26 week ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>castration</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>PSA</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>disease progression free survival</keyword>
	<keyword>DPFS</keyword>
	<keyword>dose escalation</keyword>
</DOC>